Eton Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of...
Latest News
17 hours ago · seekingalpha.com
Eton Pharmaceuticals: The Commercial Model Is Finally ScalingEton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA margin; 2026 revenue guidance increased to more than $175 million. LIBERVANT and ASN-001 are the main growth drivers, with potential launches in 2027 and 2028, respectively.
11 days ago · zacks.com
Eton Q3 Earnings Call Highlights Growth and Pipeline ExpansionETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
11 days ago · marketbeat.com
Eton Pharmaceuticals Q3 Earnings Call HighlightsEton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.
11 days ago · seekingalpha.com
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call TranscriptEton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
11 days ago · zacks.com
Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass EstimatesEton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.07 per share a year ago.
15 days ago · zacks.com
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
19 days ago · globenewswire.com
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
1 month ago · globenewswire.com
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmDEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that they have entered into an exclusive license agreement and a supply agreement covering the United States and its territories for LIBERVANT® (diazepam) buccal film, an Orphan Drug-designated, differentiated treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final U.S. Food and Drug Administration (FDA) approval.
1 month ago · zacks.com
ETON Stock Surges 108% in Six Months: Here's What You Need to KnowEton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
2 months ago · globenewswire.com
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) CapsulesDEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO® (miltefosine) capsules.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ETON